Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 11/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.40 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 6/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453173 | 1.00 | PAX8 (0.45) | PAX8APPCSNK2A1CSNK2A2MAPT | |
| SCHEMBL26510486 | 1.00 | PAX8 (0.45) | PAX8APPCSNK2A1CSNK2A2MAPT | |
| SCHEMBL29876970 | 0.94 | PAX8 (0.45) | PAX8APPCSNK2A1CSNK2A2MAPT | |
| SCHEMBL26510426 | 0.94 | PAX8 (0.45) | PAX8APPMAPTGLAGAA | |
| SCHEMBL23364317 | 0.94 | PAX8 (0.45) | PAX8APPCSNK2A1CSNK2A2MAPT | |
| SCHEMBL26510490 | 0.94 | PAX8 (0.45) | PAX8APPMAPTGLAGAA | |
| SCHEMBL23364305 | 0.93 | PAX8 (0.45) | PAX8APPMAPTGLAGAA | |
| SCHEMBL29453178 | 0.93 | PAX8 (0.45) | PAX8APPMAPTGLAGAA | |
| SCHEMBL23364366 | 0.93 | PAX8 (0.45) | PAX8APPMAPTGLAGAA | |
| SCHEMBL29874594 | 0.93 | PAX8 (0.45) | PAX8APPMAPTGLAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4337259-A1 | COMPOUNDS FOR DEGRADING ALPHA-SYNUCLEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2024-03-20 | — | — | EP | disclosed |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | APRINOIA THERAPEUTICS LIMITED (CN) | 2023-05-09 | — | — | US | disclosed |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-11-10 | — | — | US | disclosed |
| EP-4058065-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | Aprinoia Therapeutics Limited (HK) | 2022-09-21 | — | — | EP | disclosed |
| US-20220267316-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS LIMITED (CN) | 2022-08-25 | — | — | US | disclosed |
| WO-2021097243-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | APRINOIA THERAPEUTICS INC. (CN) | 2021-05-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267316-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | PAX8 3706/4885APP 3/4885CSNK2A1 1800/4885 |
| US-20230346955-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | PAX8 3706/4885APP 3/4885CSNK2A1 1800/4885 |
| US-11642413-B2 | Compounds for degrading Tau protein aggregates and uses thereof | MAPT, PRNP, APP | PAX8 3706/4885APP 3/4885CSNK2A1 1800/4885 |
| US-20220354835-A1 | COMPOUNDS FOR DEGRADING TAU PROTEIN AGGREGATES AND USES THEREOF | MAPT, PRNP, APP | PAX8 3793/4885APP 3/4885CSNK2A1 1817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.